Mechanizmy przeciwzapalnego działania ambroksolu Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2019
Słowa kluczowe:
ambroksol, mukolityki, infekcje dróg oddechowych, zapalenie
##plugins.themes.bootstrap3.article.main##
Abstrakt
Ambroksol to lek o działaniu sekretolitycznym i mukolitycznym posiadającym także wiele dodatkowych cech, których znaczenie jest nie do przecenienia. Ma właściwości przeciwzapalne, potwierdzone licznymi publikacjami z wykonanych badań in vitro i in vivo. Zmienia też biofilm dróg oddechowych i hamuje przewodzenie bólu we włóknach C. Jest lekiem o wysokiej skuteczności i bardzo dobrym profilu bezpieczeństwa u dorosłych i dzieci.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pawliczak , R. (2019). Mechanizmy przeciwzapalnego działania ambroksolu . Medycyna Faktów , 12(3(44), 276-280. https://doi.org/10.24292/01.MF.0319.16
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Beeh K.M., Beier J., Esperester A., Paul L.D.: Antiinflammatory properties of ambroxol. Eur. J. Med. Res. 2008; 13(12): 557-562.
2. Lampinen M., Rak S., Venge P.: The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin. Exp. Allergy 1999; 29(3): 314-322.
3. Su X., Wang L., Song Y., Bai C.: Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 2004; 30(1): 133-140.
4. Lee C.S., Jang Y.Y., Han E.S.: Depressant effects of ambroxol on lipopolysaccharide- or fMLP-stimulated free radical production and granule enzyme release by alveolar macrophages. Pulm. Pharmacol. Ther. 1999; 12(5): 275-284.
5. Lee C.S., Jang Y.Y., Song J.S. et al.: Ambroxol inhibits peroxynitrite-induced damage of alpha1-antiproteinase and free radical production in activated phagocytic cells. Pharmacol. Toxicol. 2002; 91(3): 140-149.
6. Seifart C., Clostermann U., Seifart U. et al.: Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol. Appl. Pharmacol. 2005; 203(1): 27-35.
7. Yang B., Yao D.F., Ohuchi M. et al.: Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19(5): 952-958.
8. Poole P.J., Black P.N.: Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322(7297): 1271-1274.
9. Schutz A., Gund H.J., Pschorn U. et al.: Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung 2002; 52(3): 194-199.
10. Fischer J., Pschorn U., Vix J.M. et al.: Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo- controlled trials regarding the local anaesthetic properties. Arzneimittelforschung 2002; 52(4): 256-263.
11. Paleari D., Rossi G.A., Nicolini G., Olivieri D.: Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin. Drug Discov. 2011; 6(11): 1203-1214.
12. Disse B.G., Ziegler H.W.: Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments. Respiration 1987; 51(supl. 1): 15-22.
13. Hull J.D., Lyon R.A.: In vitro pharmacology of ambroxol: Potential serotonergic sites of action. Life Sci. 2018; 197: 67-72.
14. de Mey C., Koelsch S., Richter E. et al.: Efficacy and Safety of Ambroxol Lozenges in the Treatment of Acute Uncomplicated Sore Throat – a Pooled Analysis. Drug Res. (Stuttg) 2016; 66(7): 384-392.
15. de Mey C., Patel J., Lakha D.R. et al.: Efficacy and Safety of an Oral Ambroxol Spray in the Treatment of Acute Uncomplicated Sore Throat. Drug Res. (Stuttg) 2015; 65(12): 658-667.
16. Malerba M., Ragnoli B.: Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 2008; 4(8): 1119-1129.
17. Ge L.T., Liu Y.N., Lin X.X. et al.: Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway. Int. Immunopharmacol. 2016; 33: 90-98.
18. Gillissen A., Bartling A., Schoen S., Schultze-Werninghaus G.: Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Lung 1997; 175(4): 235-242.
19. Gillissen A., Schärling B., Jaworska M. et al.: Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. Res. Exp. Med. (Berl.) 1997; 196(6): 389-398.
20. Gupta P.R.: Ambroxol – Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India 2010; 27(2): 46-48.
21. Lapenna D., de Gioia S., Ciofani G., Cuccurullo F.: Ambroxol is a scavenger of hypochlorous acid and monochloramine. Pharmacology 1994; 49(2): 132-135.
22. Nowak D., Antczak A., Król M. et al.: Antioxidant properties of Ambroxol. Free Radic. Biol. Med. 1994; 16(4): 517-522.
23. Stockley R.A., Shaw J., Burnett D.: Effect of ambroxol of neutrophil chemotaxis in vitro. Agents Actions 1988; 24(3-4): 292-296.
24. Bianchi M., Mantovani A., Erroi A. et al.: Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells. Agents Actions 1990; 31(3-4): 275-279.
25. Gibbs B.F.: Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues. Int. J. Immunopathol. Pharmacol. 2009; 22(4): 919-927.
26. Gao X., Huang Y., Han Y. et al.: The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch. Med. Sci. 2011; 7(3): 405-413.
27. Lu Q., Yu J., Yang X. et al.: Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int. J. Antimicrob. Agents 2010; 36(3): 211-215.
28. Stetinova V., Smetanová L., Kholová D. et al.: Transepithelial transport of ambroxol hydrochloride across human intestinal Caco-2 cell monolayers. Gen. Physiol. Biophys. 2009; 28(3): 309-315.
29. Zhang Y., Fu Y., Yu J. et al.: Synergy of ambroxol with vancomycin in elimination of catheter-related Staphylococcus epidermidis biofilm in vitro and in vivo. J. Infect. Chemother. 2015; 21(11): 808-815.
30. Nobata K., Fujimura M., Ishiura Y. et al.: Ambroxol for the prevention of acute upper respiratory disease. Clin. Exp. Med. 2006; 6(2): 79-83.
31. Cataldi M., Sblendorio V., Leo A., Piazza O.: Biofilm-dependent airway infections: a role for ambroxol? Pulm. Pharmacol. Ther. 2014; 28(2): 98-108.
32. Cazan D., Klimek L., Sperl A. et al.: Safety of ambroxol in the treatment of airway diseases in adult patients. Expert. Opin. Drug Saf. 2018; 17(12): 1211-1224.
33. Kong Q., Du X., Huang S. et al.: In vitro effects of ambroxol on Cryptococcus adherence, planktonic cells, and biofilms. APMIS 2017; 125(7): 634-640.
34. Li F., Wang W., Hu L. et al.: Effect of ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy 2011; 57(2): 173-180.
35. Wang W., Yu J., He Y. et al.: Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms. APMIS 2016; 124(7): 611-618.
36. Olivieri D., Zavattini G., Tomasini G. et al.: Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987; 51(supl. 1): 42-51.
37. Leffler A., Reckzeh J., Nau C.: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur. J. Pharmacol. 2010; 630(1-3): 19-28.
38. Deretic V., Timmins G.S.: Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert. Opin. Drug Metab. Toxicol. 2019; 15(3): 213-218.
39. Gene R., Poderoso J.J., Corazza C. et al.: Influence of ambroxol on amoxicillin levels in bronchoalveolar lavage fluid. Arzneimittelforschung 1987; 37(8): 967-968.
40. Peralta J., Poderoso J.J., Corazza C. et al.: Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. Arzneimittelforschung 1987; 37(8): 969-971.
41. Spatola J., Poderoso J.J., Wiemeyer J.C. et al.: Influence of ambroxol on lung tissue penetration of amoxicillin. Arzneimittelforschung 1987; 37(8): 965-966.
42. Villacampa J., Alcántar F., Rodríguez J.M. et al.: Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. Clin. Ther. 2003; 25(8): 2225-2232.
43. Charakterystyka leku Mucosolvan Syrop; 05.2017.
2. Lampinen M., Rak S., Venge P.: The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin. Exp. Allergy 1999; 29(3): 314-322.
3. Su X., Wang L., Song Y., Bai C.: Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 2004; 30(1): 133-140.
4. Lee C.S., Jang Y.Y., Han E.S.: Depressant effects of ambroxol on lipopolysaccharide- or fMLP-stimulated free radical production and granule enzyme release by alveolar macrophages. Pulm. Pharmacol. Ther. 1999; 12(5): 275-284.
5. Lee C.S., Jang Y.Y., Song J.S. et al.: Ambroxol inhibits peroxynitrite-induced damage of alpha1-antiproteinase and free radical production in activated phagocytic cells. Pharmacol. Toxicol. 2002; 91(3): 140-149.
6. Seifart C., Clostermann U., Seifart U. et al.: Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol. Appl. Pharmacol. 2005; 203(1): 27-35.
7. Yang B., Yao D.F., Ohuchi M. et al.: Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19(5): 952-958.
8. Poole P.J., Black P.N.: Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322(7297): 1271-1274.
9. Schutz A., Gund H.J., Pschorn U. et al.: Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung 2002; 52(3): 194-199.
10. Fischer J., Pschorn U., Vix J.M. et al.: Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo- controlled trials regarding the local anaesthetic properties. Arzneimittelforschung 2002; 52(4): 256-263.
11. Paleari D., Rossi G.A., Nicolini G., Olivieri D.: Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin. Drug Discov. 2011; 6(11): 1203-1214.
12. Disse B.G., Ziegler H.W.: Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments. Respiration 1987; 51(supl. 1): 15-22.
13. Hull J.D., Lyon R.A.: In vitro pharmacology of ambroxol: Potential serotonergic sites of action. Life Sci. 2018; 197: 67-72.
14. de Mey C., Koelsch S., Richter E. et al.: Efficacy and Safety of Ambroxol Lozenges in the Treatment of Acute Uncomplicated Sore Throat – a Pooled Analysis. Drug Res. (Stuttg) 2016; 66(7): 384-392.
15. de Mey C., Patel J., Lakha D.R. et al.: Efficacy and Safety of an Oral Ambroxol Spray in the Treatment of Acute Uncomplicated Sore Throat. Drug Res. (Stuttg) 2015; 65(12): 658-667.
16. Malerba M., Ragnoli B.: Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 2008; 4(8): 1119-1129.
17. Ge L.T., Liu Y.N., Lin X.X. et al.: Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway. Int. Immunopharmacol. 2016; 33: 90-98.
18. Gillissen A., Bartling A., Schoen S., Schultze-Werninghaus G.: Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Lung 1997; 175(4): 235-242.
19. Gillissen A., Schärling B., Jaworska M. et al.: Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. Res. Exp. Med. (Berl.) 1997; 196(6): 389-398.
20. Gupta P.R.: Ambroxol – Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India 2010; 27(2): 46-48.
21. Lapenna D., de Gioia S., Ciofani G., Cuccurullo F.: Ambroxol is a scavenger of hypochlorous acid and monochloramine. Pharmacology 1994; 49(2): 132-135.
22. Nowak D., Antczak A., Król M. et al.: Antioxidant properties of Ambroxol. Free Radic. Biol. Med. 1994; 16(4): 517-522.
23. Stockley R.A., Shaw J., Burnett D.: Effect of ambroxol of neutrophil chemotaxis in vitro. Agents Actions 1988; 24(3-4): 292-296.
24. Bianchi M., Mantovani A., Erroi A. et al.: Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells. Agents Actions 1990; 31(3-4): 275-279.
25. Gibbs B.F.: Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues. Int. J. Immunopathol. Pharmacol. 2009; 22(4): 919-927.
26. Gao X., Huang Y., Han Y. et al.: The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch. Med. Sci. 2011; 7(3): 405-413.
27. Lu Q., Yu J., Yang X. et al.: Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int. J. Antimicrob. Agents 2010; 36(3): 211-215.
28. Stetinova V., Smetanová L., Kholová D. et al.: Transepithelial transport of ambroxol hydrochloride across human intestinal Caco-2 cell monolayers. Gen. Physiol. Biophys. 2009; 28(3): 309-315.
29. Zhang Y., Fu Y., Yu J. et al.: Synergy of ambroxol with vancomycin in elimination of catheter-related Staphylococcus epidermidis biofilm in vitro and in vivo. J. Infect. Chemother. 2015; 21(11): 808-815.
30. Nobata K., Fujimura M., Ishiura Y. et al.: Ambroxol for the prevention of acute upper respiratory disease. Clin. Exp. Med. 2006; 6(2): 79-83.
31. Cataldi M., Sblendorio V., Leo A., Piazza O.: Biofilm-dependent airway infections: a role for ambroxol? Pulm. Pharmacol. Ther. 2014; 28(2): 98-108.
32. Cazan D., Klimek L., Sperl A. et al.: Safety of ambroxol in the treatment of airway diseases in adult patients. Expert. Opin. Drug Saf. 2018; 17(12): 1211-1224.
33. Kong Q., Du X., Huang S. et al.: In vitro effects of ambroxol on Cryptococcus adherence, planktonic cells, and biofilms. APMIS 2017; 125(7): 634-640.
34. Li F., Wang W., Hu L. et al.: Effect of ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy 2011; 57(2): 173-180.
35. Wang W., Yu J., He Y. et al.: Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms. APMIS 2016; 124(7): 611-618.
36. Olivieri D., Zavattini G., Tomasini G. et al.: Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987; 51(supl. 1): 42-51.
37. Leffler A., Reckzeh J., Nau C.: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur. J. Pharmacol. 2010; 630(1-3): 19-28.
38. Deretic V., Timmins G.S.: Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert. Opin. Drug Metab. Toxicol. 2019; 15(3): 213-218.
39. Gene R., Poderoso J.J., Corazza C. et al.: Influence of ambroxol on amoxicillin levels in bronchoalveolar lavage fluid. Arzneimittelforschung 1987; 37(8): 967-968.
40. Peralta J., Poderoso J.J., Corazza C. et al.: Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. Arzneimittelforschung 1987; 37(8): 969-971.
41. Spatola J., Poderoso J.J., Wiemeyer J.C. et al.: Influence of ambroxol on lung tissue penetration of amoxicillin. Arzneimittelforschung 1987; 37(8): 965-966.
42. Villacampa J., Alcántar F., Rodríguez J.M. et al.: Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. Clin. Ther. 2003; 25(8): 2225-2232.
43. Charakterystyka leku Mucosolvan Syrop; 05.2017.